Guardian Asset Advisors LLC Acquires 43 Shares of Eli Lilly and Company $LLY

Guardian Asset Advisors LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 3,516 shares of the company’s stock after purchasing an additional 43 shares during the quarter. Eli Lilly and Company accounts for about 1.6% of Guardian Asset Advisors LLC’s holdings, making the stock its 14th biggest holding. Guardian Asset Advisors LLC’s holdings in Eli Lilly and Company were worth $2,743,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Precedent Wealth Partners LLC raised its stake in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after buying an additional 39 shares in the last quarter. Capital Advisors Inc. OK raised its stake in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc bought a new position in Eli Lilly and Company in the second quarter worth approximately $54,000. Duquesne Family Office LLC raised its stake in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after buying an additional 32,640 shares in the last quarter. Finally, Corient IA LLC bought a new position in Eli Lilly and Company in the first quarter worth approximately $570,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $820.97 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market cap of $777.01 billion, a price-to-earnings ratio of 53.66, a PEG ratio of 1.16 and a beta of 0.47. The firm’s fifty day moving average is $765.52 and its two-hundred day moving average is $767.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company earned $3.92 earnings per share. The firm’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jamere Jackson bought 200 shares of the stock in a transaction dated Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LLY shares. Leerink Partners reissued a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Berenberg Bank reissued a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.